Rhizomucor pusillus, and 36 Syncephalastrum racemosum isolates. CLSI broth microdilution MICs were aggregated for the analyses. ECVs comprising >95% and >97.5% of the modeled populations were as follows: amphotericin B ECVs for L. corymbifera were 1 and 2 g/ml, those for M. circinelloides were 1 and 2 g/ml, those for R. arrhizus were 2 and 4 g/ml, and those for R. microsporus were 2 and 2 g/ml, respectively; posaconazole ECVs for L. corymbifera were 1 and 2, those for M. circinelloides were 4 and 4, those for R. arrhizus were 1 and 2, and those for R. microsporus were 1 and 2, respectively; both itraconazole ECVs for R. arrhizus were 2 g/ ml. ECVs may aid in detecting emerging resistance or isolates with reduced susceptibility (non-WT MICs) to the agents evaluated.
A lthough infections caused by filamentous fungi (molds) are not as prevalent as yeast infections, an increased incidence of systemic infections caused by Aspergillus and other mold species and more recently by members of the Mucorales (Zygomycetes) has been documented (1) (2) (3) . The order Mucorales comprises a vast variety of genera and species which have been recently reclassified according to DNA barcoding and internal transcribed spacer (ITS) ribosomal sequencing (4) . Although most Mucorales species are saprophytic, a large number of these species have been known to cause severe infections (mucormycosis, previously described as zygomycosis), especially among immunocompromised patients and/or patients with granulocytopenia, diabetes, and penetrating trauma (5-7). The recommended therapy for infections caused by the Mucorales is usually surgery and/or one of the amphotericin B lipid formulations; despite its toxicity, amphotericin B deoxycholate continues to be used routinely in some areas (5, 8) . More recently, posaconazole has been recommended as salvage therapy and/or prophylaxis (9) (10) (11) ; itraconazole and other triazoles are also used as prophylactics (9) . Despite antifungal therapy, mucormycosis is associated with a great deal of morbidity and about a 50% mortality rate; breakthrough infections caused by Mucorales species among patients receiving triazole prophylaxis, especially voriconazole, are frequently reported (3, 6) .
The Clinical and Laboratory Standards Institute (CLSI) Subcommittee on Antifungal Susceptibility Tests has developed a reproducible procedure for the antifungal susceptibility testing of Mucorales species as described in the M38-A2 broth microdilution document (12) . However, although species-specific formal clinical breakpoints (CBPs) and/or epidemiological cutoff values (ECVs) have been established for Candida spp. and Aspergillus spp. (13) (14) (15) (16) , neither MIC distributions nor ECVs are available for any Mucorales species. The establishment of CBPs for mold species has been hampered by the low incidence of these infections and the scarcity of the data required for their development, including both low and high MICs that might predict clinical failure. However, ECVs are calculated based on MIC distributions (Ͼ100 MICs/species/agent) from multiple independent laboratories (Ն3) (14, 16, 17) . Although amphotericin B and triazole MIC data have been reported for a variety of genera belonging to the Mucorales, available data are mostly for the more prevalent species, and the number of isolates evaluated is small (18) (19) (20) (21) (22) .
The purpose of the study was (i) to define wild-type (WT) susceptibility endpoint MIC distributions of 10 Mucorales species using CLSI M38-A2 broth microdilution MIC data originating from 3 to 14 laboratories and (ii) to propose ECVs for amphotericin B, posaconazole, and itraconazole for four common Mucorales species (Lichtheimia [Absidia] corymbifera, Mucor circinelloides, Rhizopus arrhizus [Rhizopus oryzae], and Rhizopus microsporus) when the number of CLSI MICs was Ն112 for the species/agent combination originating from Ն8 independent laboratories. Amphotericin B, posaconazole, and itraconazole MIC distributions comprising 10 to 93 isolates for the less prevalent species (e.g., Apophysomyces variabilis, Cunninghamella bertholletiae, Mucor indicus, Mucor ramosissimus, Rhizomucor pusillus, and Syncephalastrum racemosum) also are documented. We aggregated a total of 10 to 349 MICs (species and antifungal agent dependent) obtained in 14 independent laboratories (Argentina, Australia, Canada, Europe, India, Mexico, and the United States).
MATERIALS AND METHODS
Isolates. The isolates evaluated were recovered from patients with mostly five types of infection: rhinocerebral, pulmonary, skin, bone, cerebral (sometimes both cerebral and cutaneous or pulmonary and cutaneous), and abdominal. The most common clinical specimens were nasal or palate biopsy specimens, aspirates, swabs, or scrapes; pulmonary secretions; pleural fluids; computed tomography-guided fine-needle aspirates; and bronchoalveolar lavage and endotracheal aspirates. Antifungal susceptibility testing was performed according to the CLSI broth microdilution method (M38-A2) at the following medical centers: VCU Tables 1 to 4 . Overall, these isolates represented the unique isolate recovered from each infection and were likely WT strains, but there is no information regarding the prior exposure to antifungal therapy. This could be a possible limitation of the study, as prior exposure may result in acquired antifungal resistance, skewing the results.
Three quality control (QC) strains, Candida parapsilosis ATCC 22019, Candida krusei ATCC 6258, and Paecilomyces variotii ATCC MYA-3630, and one reference isolate, Aspergillus flavus ATCC 204304, were used by the participant laboratories (12, 13) .
Antifungal susceptibility testing. In order to include MIC results in the set of aggregated data from the 14 laboratories (Tables 1 to 3 ), amphotericin B and triazole MICs were obtained at each center by following the CLSI M38-A2 broth microdilution method (RPMI 1640 broth containing 0.2% dextrose, inoculum concentrations of ϳ10 4 CFU/ml, and 24 h of incubation) (12) . The MICs were the lowest drug concentrations that showed 100% growth inhibition or the first clear well compared to the growth control. At least one of the three QC or reference strains were utilized during the years of testing in each center; these MICs were within the recommended MIC limits (13) with one exception. The agreement was 97% for C. krusei and amphotericin B (one dilution lower than established range), but the modes were within one dilution.
Definitions. The WT population is the subpopulation of isolates in a species-drug combination without detectable acquired resistance mechanisms (17) . The ECV is the highest WT susceptibility endpoint; this endpoint has also been defined as the WT cutoff value (CO WT ). In other words, the ECV is the critical drug concentration that may identify those strains with decreased susceptibility to the agent being evaluated or the non-WT isolates harboring resistant mechanisms (14, 16, 17) .
Data analysis. The MIC distribution of each species-agent combination from each laboratory was listed in an Excel spreadsheet; the MIC data were reviewed for obvious outlier results and abnormalities, e.g., skewed distributions ("truncated" [mode at the lowest concentration tested] or bimodal distributions within an apparent wild type). These abnormal distributions were not included in the analysis, and outliers were not observed. Next, the presumptive WT modal MICs were determined for each species-agent combination and laboratory followed by obtaining the pooled MIC distributions for each antifungal agent and Mucorales species with the qualifying data. ECVs were calculated for each distribution and species by the previously reported iterative statistical technique (17) . Briefly, the modeled population is based on fitting a lognormal distribution to increasing subsets of the data starting at that population that includes isolates with MICs one dilution higher than the mode (or than the lower mode if there was more than one mode) and determining the mean and standard deviation of the cumulative lognormal distribution that best fits those data; those numbers were used to calculate the MIC that captures at least 95% and 97.5% of the modeled WT population (not the observed MIC population). In addition, we evaluated the inherent variability (approximately within one doubling dilution) of susceptibility testing and the presence of outlier laboratories in each pooled distribution (24) .
RESULTS AND DISCUSSION
For susceptibility testing to be useful in the clinical setting, MIC results should be reliable and must classify the infecting isolate as either resistant (nontreatable) or susceptible (treatable) to the antimicrobial agent being evaluated (25, 26) . So far, we do not have susceptibility endpoints that would allow such classification for any combination of an antifungal agent and a species belonging to the order Mucorales. The data needed to propose CBPs for these species and any antifungal agent are not available. However, we have gathered sufficient CLSI MICs to propose ECVs of amphotericin B and two triazoles and for four species of Mucorales and to provide MIC distributions for another six less prevalent species. While a total of 15 laboratories submitted MICs of amphotericin B and both triazoles, the distributions for between 1 and 2 laboratories (depending on the antifungal agent and species) were not included in the final analysis due to truncated (modal MIC at the lowest concentration tested) or bimodal ("saddle" between two modes) distributions; itraconazole data were not provided by some laboratories. In addition, several data from one of the laboratories were omitted due to the use of RPMI broth with 2% glucose (rather than 0.2% prescribed by CLSI) (12) . Although some of the laboratories also submitted voriconazole data, most of the modal MICs for the different species were 16 g/ml; the exception was the voriconazole mode of 8 g/ml for 235 isolates of R. arrhizus originating in 11 laboratories (data not shown in Tables 1 to 3 ).
The resulting pooled MIC distributions for the three agents and species evaluated as submitted by 3 to 14 laboratories are depicted in Tables 1 to 3 . Evaluation of the pooled MIC distributions indicated that the majority of distributions for each antifungal agent and species were typical for WT organisms (3 to 5 2-fold dilution concentrations surrounding the modal MIC) and that the distributions from each laboratory were comparable as their modal MICs for each species-agent combination were mostly within 1 2-fold dilution of one another. The exceptions were amphotericin B modes for R. arrhizus (modes of 0.5 to 1 g/ml in 11 of 12 laboratories, while the mode was 0.25 g/ml in one laboratory) and itraconazole modes for L. corymbifera (modes of 0.25 to 0.5 g/ml in 8 of 9 laboratories, while the mode was 1 g/ml in one laboratory (data not shown in Tables 1 and 3 ). The latter modal discrepancy accounts for the three similar "bars" observed in the pooled itraconazole and L. corymbifera distribution (Table 3) . Amphotericin B modes were species dependent and ranged from 0.06 g/ml (S. racemosum) to 2 g/ml (C. bertholletiae) ( Table 1) . In contrast to amphotericin B, most posaconazole modes were 0.5 g/ml; the exceptions were modes of 0.25 g/ml (R. pusillus) and 1 g/ml (M. circinelloides and A. variabilis). Physiological, genetic, and morphological data have indicated that the most clinically relevant species is A. variabilis (27) . Data submitted for two other species in this genus (Apophysomyces ossiformis and Apophysomyces trapeziformis) were insufficient to list in Tables 1 to 3 . A wider modal range (0.25 to 4 g/ml) was observed with itraconazole, as it was for amphotericin B, among the fewer species evaluated, with the lower mode for L. corymbifera, R. pusillus, and S. racemosum and the highest value for M. circinelloides, as it was for posaconazole (Tables 2 and 3 ). Again, some of these distributions are small. On the whole, these results underline the need for identification to the species level as well as for antifungal susceptibility testing.
The in vitro activities of the three antifungal agents evaluated are similar to those previously reported for most of the species. In some instances, the pooled amphotericin B MIC ranges were wider for L. corymbifera, M. circinelloides, and R. pusillus than previously reported (MIC range for the three species, 0.03 to 16 g/ml [ Table 1 ] versus 0.01 to 0.5 g/ml) (19, 21, 22) , but the number of isolates for these three species was lower (5 to 20 isolates) in those studies and therefore not a good representation of their susceptibility to amphotericin B. A similar discrepancy in MIC ranges was also observed with the triazole data (21, 22) , but the most frequent MIC (when provided) was similar to those in the present study. In contrast, in our pooled distributions of C. bertholletiae (Tables 1 to 3) , the highest MICs of the three agents ranged between 1 and 8 g/ml, versus reported values of 8 to Ն64 g/ml for sets of Ͻ7 isolates (19, 21) . Based on these data and the widespread geographical area from which we received our MIC data, we surmise that the data are valid.
The CLSI has made a final decision regarding what ECV percentage (the Ն95% or the Ն97.5% value) to recommend in the CLSI document that is under development for this purpose; the lower percentage risks classifying some WT isolates as non-WT isolates, while the selected higher ECV percentage risks classifying some isolates with acquired resistance mechanisms as WT. Because of that, Table 4 depicts amphotericin B, posaconazole, and itraconazole ECVs for the aggregated distributions of four species of Mucorales where the data originated in 8 to 14 laboratories and comprised Ͼ100 MICs for each species and agent evaluated (using the methods that comprised Ն95% and Ն97.5% of the modeled populations). The CLSI amphotericin B ECV comprising Ն95% of the modeled populations is 1 g/ml for L. corymbifera and M. circinelloides and 2 g/ml for R. arrhizus and R. microsporus; however, ECVs comprising Ն97.5% of the modeled populations were one dilution higher with the exception of R. microsporus (both ECVs were 2 g/ml). It is noteworthy that an amphotericin B MIC of 2 g/ml is anecdotally considered to be the "breakpoint" for resistance and yet here and among some Aspergillus spp. (15) may be perceived as a WT value. The ECV of posaconazole for L. corymbifera, R. arrhizus, and R. microsporus is 1 g/ml (comprising Ն95% of the modeled populations), while the ECV for M. circinelloides is 4 g/ml. Posaconazole ECVs comprising Ն97.5% of the modeled populations were also one dilution higher, with the exception of the ECV of 4 g/ml for M. circinelloides. Regarding itraconazole, we are proposing a 2-g/ml ECV for R. arrhizus, encompassing both Ն95% and 97.5% of the modeled populations. We did not receive sufficient itraconazole data to propose ECVs for any other species or to propose amphotericin B and posaconazole ECVs for the less prevalent species. Nevertheless, the distributions for the species for which ECVs were not proposed of the three agents are depicted in Tables 1 to 3 .
The frequency of amphotericin B and triazole MICs above the ECV (non-WT) varied according to the distribution analyzed (Table 4) ; it was lower for all species versus amphotericin B (0% to 2.9%) than for all species versus posaconazole (0.9% to 10.9%) (ECVs encompassing Ն95% and Ն97.5% of the MIC populations). As expected, the Ն95% analysis provided the highest rates of non-WT MICs: 2.9% among L. corymbifera versus amphotericin B and 10.9% for R. arrhizus and posaconazole. Acquired azole resistance in mold isolates has been studied mostly in Aspergillus isolates. Targeted disruption of the cyp51A gene in azole-susceptible A. fumigatus isolates has yielded strains with decreased azole susceptibility (MICs Ͼ 2 g/ml) and a reduced concentration of intracellular drug; triazole MICs of Ͼ4 g/ml for isolates of Aspergillus spp. are associated with clinical failure (28) . In a similar manner, the relationship between resistance mechanisms, high (29, 30) . On the other hand, antifungal mechanisms of resistance in the Mucorales are areas that deserve future investigation; to our knowledge, no information is available regarding resistance mechanisms of either amphotericin B or posaconazole in these molds despite the fact that they are the recommended therapeutic agents for mucormycosis. Despite the prolonged use of amphotericin B, its mechanisms of action and/or resistance are not completely understood; however, overall, resistance to this agent is considered rare. It is expected that mutations similar to those found in other molds could be found among non-WT isolates of the Mucorales versus either amphotericin B or posaconazole. For these molds and antifungal agents, correlations between MICs and clinical response to therapy were not found in the literature, even though large numbers of mucormycosis cases have been reported. To compound the problem, cultures are not always available, since other methods of diagnosis are usually performed to promptly initiate therapy, e.g., histopathology (5, 31) . Outcome is also influenced by the site of infection, the underlying disease, and other factors. However, the correlation of posaconazole MICs and treatment outcome in experimental, disseminated mucormycosis has been evaluated with a variety of Mucorales species. In two of these murine models, immunosuppressed animals infected with either R. arrhizus or R. microsporus isolates (posaconazole MICs, 2 g/ml and 0.25 g/ml for each species), survival was higher (30 to 40 versus 10 to 20%) when animals were infected with isolates with the lower MICs (32, 33) . In another study, survival was strain dependent, although posaconazole MICs for both infected strains were low (0.03 and 0.12 g/ml); however, posaconazole and amphotericin B prolonged survival among neutropenic mice infected with an isolate of L. corymbifera for which MICs of both agents were 0.06 to 1 g/ml (34). According to our proposed posaconazole ECV for L. corymbifera and R. microsporus, isolates with the lower MICs and good response to treatment could be considered WT using the values that comprised Ն95% of the modeled populations; the same applies to all infective R. arrhizus isolates ( Table 4) . The response to posaconazole treatment was also found to be uncertain in two M. circinelloides models; efficacy was reported as good when survival was compared to that in nonimmunosuppressed control animals but variable with regard to reduction of tissue burden (35, 36) . The posaconazole ECV for M. circinelloides is 4 g/ml, and the isolates evaluated in those two studies could be considered either non-WT (MIC of the infecting isolate, 8 g/ml) (35) or WT (MICs of the infecting isolates, 1 to 4 g/ml) (36) . The MIC in the first study was determined at 48 h instead of 24 h. Mechanisms of resistance were not evaluated in any of those strains, because as mentioned above, the molecular biology of the Mucorales is not as developed as that of Candida and Aspergillus.
In conclusion, we propose species-specific amphotericin B ECVs comprising Ն95% of the modeled populations of 1 g/ml (L. corymbifera and M. circinelloides) to 2 g/ml (R. arrhizus and R. microsporus), posaconazole ECVs of 1 g/ml (L. corymbifera, R. arrhizus, and R. microsporus) to 4 g/ml (M. circinelloides), and an itraconazole ECV of 2 g/ml for R. arrhizus. ECVs were mostly one dilution higher when Ն97.5% of the modeled populations was used. Our results cover amphotericin B and its lipid formulations because their MIC data have been comparable (29) . Further studies should determine the relationship between molecular mechanisms of resistance and our proposed amphotericin B and triazole non-WT values. Although ECVs do not predict clinical response to therapy, they should be considered for inclusion in future CLSI documents regarding the setting and use of ECVs. Similar to the ECVs for Candida spp. and Aspergillus spp., the proposed ECVs for the Mucorales may aid in the detection of strains with acquired mechanisms of resistance (non-WT) to the agents evaluated in the present study.
